Opexa Therapeutics held a conference call Conference call to discuss the option and license agreement with Merck Serono for development of Tcelna for treatment of Multiple Sclerosis was held on February 5 at 8:30 am and has a webcasted replay available. Webcast Link
Opexa Therapeutics to present biomarker data from NMO patients at AAN meeting Opexa Therapeutics announced that it has been invited to present data on the immune profile of patients with NMO at the 67th American Academy of Neurology Annual Meeting in Washington D.C. Opexa will present the results of a study conducted to characterize the cellular immune profile of NMO patients prescribed B-cell depleting therapy in comparison to those of healthy donors. The results showed that despite administration of B-cell depleting therapy, inflammation continued to persist as did the presence of activated T-cells. Opexa has a preclinical development program in NMO and IND enabling activities are currently being conducted with its drug development candidate, OPX-212.